A 12-week treatment with fractional CO2 laser for vulvovaginal atrophy: A pilot study

Climacteric

Volumn 17, Issue 4, 2014, Pages 363-369

  Salvatore, S ^a   Nappi, R E ^b   Zerbinati, N ^c   Calligaro, A ^b   Ferrero, S ^d   Origoni, M ^a   Candiani, M ^a   Leone Roberti Maggiore, Umberto ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c UNIVERSITY OF INSUBRIA   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

Author keywords

Dyspareunia; Menopause; Vaginal Dryness; Vulvovaginal Atrophy

Indexed keywords

ADULT; ARTICLE; CARBON DIOXIDE LASER; CLINICAL ARTICLE; DYSPAREUNIA; DYSURIA; ESTROGEN THERAPY; FEMALE; FOLLOW UP; HUMAN; PAIN ASSESSMENT; PATIENT SATISFACTION; PILOT STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; SCORING SYSTEM; SHORT FORM 12; SYMPTOM; TREATMENT DURATION; VAGINA ATROPHY; VAGINAL BURNING SENSATION; VAGINAL DRYNESS; VAGINAL PRURITUS; VISUAL ANALOG SCALE; ATROPHY; COMPLICATION; DEVICES; FEASIBILITY STUDY; GAS LASER; LOW LEVEL LASER THERAPY; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; PSYCHOLOGY; RADIATION RESPONSE; THERAPEUTIC USE; TREATMENT OUTCOME; VAGINA; VAGINAL DISEASES; VULVA; VULVAR DISEASES;

ATROPHY; DYSPAREUNIA; FEASIBILITY STUDIES; FEMALE; HUMANS; LASER THERAPY, LOW-LEVEL; LASERS, GAS; MIDDLE AGED; PILOT PROJECTS; POSTMENOPAUSE; QUALITY OF LIFE; TREATMENT OUTCOME; VAGINA; VAGINAL DISEASES; VULVA; VULVAR DISEASES;

EID: 84904327368     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697137.2014.899347     Document Type: Article

References (49)

1. Castelo-Branco C, Cancelo MJ, Villero J, Nohales F, Juliá MD. Management of post-menopausal vaginal atrophy and atrophic vaginitis. Maturitas 2005 ; 52 : S46-52
2. Calleja-Agius J, Brincat M P. Urogenital atrophy. Climacteric 2009 ; 12 : 279-85
3. Archer DF. Efficacy and tolerability of local estrogen therapy for urogenital atrophy. Menopause 2010 ; 17 : 194-203
4. Mehta A, Bachmann G. Vulvovaginal complaints. Clin Obstet Gynecol 2008 ; 51 : 549-55
5. Simon J A. Identifying and treating sexual dysfunction in postmenopausal women: the role of estrogen. J Womens Health (Larchmt) 2011 ; 20 : 1453-65
6. Levine K B, Williams R E, Hartmann K E. Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women. Menopause 2008 ; 5 : 661-6
7. Goldstein I. Recognizing and treating urogenital atrophy in postmenopausal women. J Womens Health (Larchmt) 2010 ; 19 : 425-32
8. Santoro N, Komi J. Prevalence and impact of vaginal symptoms among postmenopausal women. J Sex Med 2009 ; 6 : 2133-42
9. Pastore LM, Carter RA, Hulka BS, Wells E. Self-reported urogenital symptoms in postmenopausal women: Women's Health Initiative. Maturitas 2004 ; 49 : 292-303
10. Palacios S. Managing urogenital atrophy. Maturitas 2009 ; 63 : 315-18
11. Nappi R E, Lachowsky M. Menopause and sexuality: prevalence of symptoms and impact on quality of life. Maturitas 2009 ; 63 : 138-41
12. Parish SJ, Nappi RE, Krychman ML, et al. Impact of vulvovaginal health on postmenopausal women: a review of surveys on symptoms of vulvovaginal atrophy. Int J Womens Health 2013 ; 5 : 437-47
13. Nappi RE, Palacios S. Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause. Climacteric 2014 ; 17 : 3-9
14. Nappi R E, Kokot-Kierepa M. Women's voices in the menopause: results from an international survey on vaginal atrophy. Maturitas 2010 ; 67 : 233-8
15. Nappi R E, Kokot-Kierepa M. Vaginal Health: Insights, Views and Attitudes (VIVA)-results from an international survey. Climacteric 2012 ; 15 : 36-44
16. Nappi R E, Kingsberg S, Maamari R, Simon J. The CLOSER (Clarifying Vaginal Atrophy's Impact On Sex and Relationships) Survey: Implications of vaginal discomfort in postmenopausal women and in male partners. J Sex Med 2013 ; 10 : 2232-41
17. Sturdee DW, Panay N ; International Menopause Society Writing Group. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric 2010 ; 13 : 509-22
18. Rees M, Pérez-López FR, Ceasu I, et al. EMAS clinical guide: low-dose vaginal estrogens for postmenopausal vaginal atrophy. Maturitas 2012 ; 73 : 171-4
19. NAMS. Management of symptomatic vulvovaginal atrophy: 2013 position statement of the North American Menopause Society. Menopause 2013 ; 20 : 888-902
20. Portman DJ, Bachmann GA, Simon JA ; Ospemifene Study Group. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause 2013 ; 20 : 623-30
21. Goldstein S R, Bachmann G A, Koninckx P R, Lin V H, Portman DJ, Ylikorkala O ; the Ospemifene Study Group. Ospemifene 12-month safety and effi cacy in postmenopausal women with vulvar and vaginal atrophy. Climacteric 2014 ; 17 : 173-82
22. Shulman LP, Portman DJ, Lee WC, et al. A retrospective managed care claims data analysis of medication adherence to vaginal estrogen therapy: implications or clinical practice. J Womens Health (Larchmt) 2008 ; 17 : 569-78
23. Kingsberg S A, Wysocki S, Magnus L, Krychman ML. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey. J Sex Med 2013 ; 10 : 1790-9
24. Kingsberg S A, Krychman M L. Resistance and barriers to local estrogen therapy in women with atrophic vaginitis. J Sex Med 2013 ; 10 : 1567-74
25. Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2006 Oct 18;(4):CD001500
26. Sadovsky R, Basson R, Krychman M, et al. Cancer and sexual problems. J Sex Med 2010 ; 7 : 349-73
27. Pruthi S, Simon JA, Early AP. Current overview of the management of urogenital atrophy in women with breast cancer. Breast J 2011 ; 17 : 403-8
28. Sinha A, Ewies AA. Non-hormonal topical treatment of vulvovaginal atrophy: an up-to-date overview. Climacteric 2013 ; 16 : 305-12
29. Berlin AL, Hussain M, Phelps R, Goldberg DJ. A prospective study of fractional scanned nonsequential carbon dioxide laser resurfacing: a clinical and histopathologic evaluation. Dermatol Surg 2009 ; 35 : 222-8
30. Ong MW, Bashir SJ. Fractional laser resurfacing for acne scars: a review. Br J Dermatol 2012 ; 166 : 1160-9
31. Tierney EP, Hanke CW. Fractionated carbon dioxide laser treatment of photoaging: prospective study in 45 patients and review of the literature. Dermatol Surg 2011 ; 37 : 1279-90
32. Tierney EP, Hanke CW. Ablative fractionated CO2, laser resurfacing for the neck: prospective study and review of the literature. J Drugs Dermatol 2009 ; 8 : 723-31
33. Peterson JD, Goldman MP. R ejuvenation of the aging chest: a review and our experience. Dermatol Surg 2011 ; 37 : 555-71
34. Salvatore S, Digesu G, Siesto G, et al. Vaginal collagen remodelling after fractional carbon dioxide laser surgery [abstract 233]. Presented at Annual Meeting of the International Continence Society, Glasgow, United Kingdom, August-September 2011
35. Ettinger B, Hait H, Reape KZ, Shu H. Measuring symptom relief in studies of vaginal and vulvar atrophy: the most bothersome symptom approach. Menopause 2008 ; 15 : 885-9
36. Bump RC, Mattiasson A, Bo K, et al. The standardization of terminology of female pelvic organ prolapse and pelvic fl oor dysfunction. Am J Obstet Gynecol 1996 ; 175 : 10-17
37. Bachmann GA, Notelovitz M, Kelly SJ, et al. Long-term nonhormonal treatment of vaginal dryness. Clin Pract Sexuality 1992 ; 8 : 3-8
38. Ware J, Kosinski M, Keller SD. A 12-item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996 ; 34 : 220-33
39. Christensen K, Doblhammer G, Rau R, Vaupel JW. Ageing populations: The challenges ahead. Lancet 2009 ; 374 : 1196-208
40. Brincat MP, Baron YM, Galea R. Estrogens and the skin. Climacteric 2005 ; 8 : 110-23
41. Sartori MG, Feldner PC, Jarmy-Di Bella ZI, et al. Sexual steroids in urogynecology. Climacteric 2011 ; 14 : 5-14
42. de Villiers TJ, Pines A, Panay N, et al. on behalf of the International Menopause Society. Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric 2013 ; 16 : 316-37
43. Nappi R E, Davis S R. The use of hormone therapy for the maintenance of urogynecological and sexual health post WHI. Climacteric 2012 ; 15 : 267-74
44. Fournier A, Kernaleguen C, Panjo H, Clavel-Chapelon F, Ringa V. Postmenopausal hormone therapy initiation before and after the Women's Health Initiative in two French cohorts. Menopause 2011 ; 18 : 219-23
45. Chin SN, Trinkaus M, Simmons C, et al. Prevalence and severity of urogenital symptoms in postmenopausal women receiving endocrine therapy for breast cancer. Clin Breast Cancer 2009 ; 9 : 108-17
46. Biglia N, Moggio G, Peano E, et al. Effects of surgical and adjuvant therapies for breast cancer on sexuality, cognitive functions, and body weight. J Sex Med 2010 ; 7 : 1891-900
47. Longo C, Galimberti M, De Pace B, Pellacani G, Bencini P L. Laser skin rejuvenation: epidermal changes and collagen remodeling evaluated by in vivo confocal microscopy. Lasers Med Sci 2013 ; 28 : 769-76
48. Kohl E, Meierhöfer J, Koller M, et al. Fractional carbon dioxide laser resurfacing of rhytides and photoaging: a prospective study using profi lometric analysis. Br J Dermatol 2013 ; 170 : 858-65
49. Doumouchtsis SK, Chrysanthopoulou EL. Urogenital consequences in ageing women. Best Pract Res Clin Obstet Gynaecol 2013 ; 27 : 699-714